NCT01073631已完成不适用
Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 543
- 主要终点
- Percentage of Participants With Categorical Clinical Response: Cure, Improvement, Failure, or Unevaluable
研究概览
简要总结
This is a non-interventional study of voriconazole tablet in Korea which is mandated by the Korean government agency.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are indicated for voriconazole table according to the drug package insert.
排除标准
- 未提供
研究组 & 干预措施
1
Patients who are indicated for use of voriconazole tablet.
干预措施: voriconazole tablet (Drug)
结局指标
主要结局
Percentage of Participants With Categorical Clinical Response: Cure, Improvement, Failure, or Unevaluable
时间窗: Baseline (Day 1) up to 2.1 Years
Clinical response defined as: Cure=resolution of all baseline signs and symptoms of fungal infection(s); Improvement=lessening of baseline signs and symptoms or absence of one or more, but not all baseline findings; Failure=no improvement or deterioration of baseline condition; Unevaluable=incomplete therapy (efficacy could not be evaluated or discontinuation was not followed up).
次要结局
- Percentage of Participants With Cultivated Strain Mycological Response: Eradication, Persistence, Superinfection, or Not Evaluable(Baseline (Day 1) up to 2.1 Years)
研究者
相似试验
已完成
不适用
Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IVSerious Fungal InfectionsNCT01073618Pfizer692
已完成
不适用
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast CancerBreast CancerNCT01047358Pfizer206
已完成
不适用
Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547)Fungal InfectionsNCT01436578Merck Sharp & Dohme LLC273
已完成
不适用
Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In KoreaDiabetes Mellitus Type 2NCT02090673AstraZeneca1,711
已完成
不适用
Korean Post-marketing Surveillance for Onglyza®Diabetes Mellitus, Type 2NCT01575483AstraZeneca3,433